Review of common adverse effects of selected antiarrhythmic drugs

The Antiarrhythmic and Hypotensive Effects of S-61 and S-73, the Pyrrolidin-2-one Derivatives with α1-Adrenolytic Properties

Heart rhythm abnormalities are a cause of many deaths worldwide. Unfortunately, the available antiarrhythmic drugs show limited efficacy and proarrhythmic potential. Thus, efforts should be made to search for new, more effective, and safer pharmacotherapies. Several studies suggested that blocking the α₁-adrenoceptors could restore normal heart rhythm in arrhythmia. In this study, we aimed to assess the antiarrhythmic potential of S-61 and S-73, two novel pyrrolidin-2-one derivatives with high affinity for α₁-adrenergic receptors. First, using radioligand binding studies, we demonstrated that S-61 and S-73 did not bind with β₁-adrenoceptors. Next, we assessed whether S-61 and S-73 could protect rats against arrhythmia in adrenaline-, calcium chloride- and aconitine-induced arrhythmia models. Both compounds showed potent prophylactic antiarrhythmic properties in the adrenaline-induced arrhythmia model, but the effect of S-61 was more pronounced. None of the compounds displayed antiarrhythmic effects in calcium chloride- or aconitine-induced arrhythmia models. Interestingly, both derivatives revealed therapeutic antiarrhythmic activity in the adrenaline-induced arrhythmia, diminishing heart rhythm irregularities. Neither S-61 nor S-73 showed proarrhythmic potential in rats. Finally, the compounds decreased blood pressure in rodents. The hypotensive effects were not observed after coadministration with methoxamine, which suggests the α₁-adrenolytic properties of both compounds. Our results confirm that pyrrolidin-2-one derivatives possess potent antiarrhythmic properties. Given the promising results of our experiments, further studies on pyrrolidin-2-one derivatives might result in the development of a new class of antiarrhythmic drugs.

Current treatment options for atrial flutter and results with cryocatheter ablation

Rhythm disturbances arising in the upper chambers of the heart are not uncommon. They are associated with a heavy burden of illness for the affected individual, as well as society in general. Atrial flutter, a re-entrant atrial tachycardia, is one such rhythm disturbance. The objective of this review article is twofold: first, to provide a brief insight into atrial flutter and the typical treatments for this arrhythmia in clinical practice; and second, to give an in-depth account of cryocatheter ablation as a relatively new treatment option for this potentially debilitating condition. The many recent clinical studies documenting the use of cryocatheter ablation for treatment of atrial flutter are presented, and their results briefly discussed. Overall, as cryocatheter ablation embeds itself among the arsenal of treatments for atrial flutter, the promising results from clinical studies appear destined to elevate cryocatheter ablation to a premier position among the treatment options for atrial flutter.

Atrial flutter: a focus on treatment options for a common supraventricular tachyarrhythmia

Atrial flutter (AFl), a re-entrant atrial tachycardia, is a cardiac rhythm disturbance that arises in the upper chambers of the heart. This usually non-life-threatening condition can be treated by a number of medical intervention strategies, which include electrical cardioversion, pharmacological therapy, and catheter ablation. These options have been available in clinical practice for a number of years. However, catheter ablation, in the form of radiofrequency catheter ablation and cryo catheter ablation, is increasingly utilised as a first-line treatment option for AFl in certain patients. The purpose of this review article is two-fold: first, to briefly present an overview of AFl and the more familiar treatment options for this arrhythmia, and second to provide more in-depth coverage of catheter ablation technologies as a treatment option for patients with AFl. As part of the latter objective, recent clinical studies documenting the use of radiofrequency catheter ablation and cryo catheter ablation for AFl are presented and their results briefly discussed.

Medications and the elderly in the critical care setting

As the elderly population in our country continues to increase, it is imperative that the bedside practitioner be keenly aware of the factors that affect pharmacokinetics and pharmacodynamics of medication administration. Refining the admission interview process to obtain accurate medication information--including alternative and OTC drugs--will help to decrease the incidence of drug interactions and ADR in the acute care setting. Appropriate monitoring of pharmacologic effects and organ function will allow the practitioner to better treat the elderly client with as few medications as possible.